Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CW2IP2: Imaging Proteinopathies With PET
NCT06932809Phase 1Recruiting
- Sponsor
- University of Pennsylvania
- Start
- May 2025
- Primary completion
- Apr 2030
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 18F-JSS20-183A in tauopathy, progressive supranuclear palsy (PSP), Corticobasal Syndrome (CBS) and 3 more, sponsored by University of Pennsylvania. Primary endpoints: Organ Biodistribution or Dosimetry at 4 weeks and PET Uptake of Tracer at 4 weeks. Started May 2025; status: recruiting.
02
Drugs
18F-JSS20-183A
03
Conditions
tauopathyprogressive supranuclear palsy (PSP)Corticobasal Syndrome (CBS)Fronto-temporal lobar degeneration (FTLD)Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06932809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06932809.